View Older Stories View More Recent Stories

May 12, 2022 08:37AM Moleculin Biotech (MBRX) Reports Q1 Result
May 12, 2022 08:35AM Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
May 10, 2022 08:35AM Moleculin Biotech (MBRX) Approved by UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122
May 10, 2022 08:35AM Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
May 5, 2022 08:15AM Moleculin Biotech (MBRX) Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia
May 5, 2022 08:15AM Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
May 4, 2022 08:15AM Moleculin Biotech (MBRX) Appoints Wolfram C. M. Dempke as European Chief Medical Officer
May 4, 2022 08:15AM Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer
Apr 21, 2022 08:49AM Moleculin Biotech (MBRX) Cleared to Conduct Phase 1 Study of WP1066
Apr 21, 2022 08:47AM Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma
Apr 14, 2022 08:06AM Moleculin Biotech (MBRX) Announces Corporate Rebranding
Apr 14, 2022 08:05AM Moleculin Announces Corporate Rebranding and Launch of New Website
Apr 8, 2022 01:05PM Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting
Apr 8, 2022 01:05PM /C O R R E C T I O N -- Moleculin Biotech, Inc./
Mar 25, 2022 07:06AM Moleculin Biotech (MBRX) Issues FY21 Update
Mar 25, 2022 07:05AM Moleculin Reports Full Year Financial Results and Provides Programs Update
Mar 23, 2022 08:05AM Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Mar 11, 2022 08:05AM Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference
Mar 1, 2022 08:35AM Moleculin Biotech (MBRX) Appoints Joy Yan to its Board
Mar 1, 2022 08:35AM Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors
Feb 14, 2022 09:05AM Moleculin Biotech (MBRX) Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
Feb 14, 2022 09:05AM Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
Jan 20, 2022 08:40AM Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference
Jan 18, 2022 08:05AM Moleculin Biotech (MBRX) Reports Updated Preliminary Safety Data for Annamycin
Jan 18, 2022 08:05AM Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma
Jan 12, 2022 10:35AM JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
Jan 7, 2022 08:30AM Moleculin to Present at the H.C. Wainwright BioConnect Conference
Dec 27, 2021 08:05AM Moleculin Biotech (MBRX) Reports Prelim Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Dec 27, 2021 08:05AM Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Dec 1, 2021 08:37AM Moleculin Biotech (MBRX) Granted FDA Clearance for Phase 1 Study of WP1122
Dec 1, 2021 08:35AM Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme
Nov 12, 2021 08:05AM Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event
Nov 11, 2021 08:05AM Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update
Nov 4, 2021 02:30PM JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
Oct 19, 2021 09:05AM Moleculin Biotech (MBRX) Receives Authorization from MHRA to Commence Phase 1a Clinical Trial of WP1122 for Treatment of COVID-19
Oct 19, 2021 09:05AM Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Oct 18, 2021 08:26AM Moleculin (MBRX) Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for Treatment of Soft Tissue Sarcoma Lung Metastases
Oct 18, 2021 08:25AM Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Sep 27, 2021 07:05AM Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference
Sep 17, 2021 08:05AM Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Sep 8, 2021 08:00AM Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 12, 2021 08:18AM Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
Jul 13, 2021 08:39AM Moleculin Biotech (MBRX) Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia
Jul 13, 2021 08:35AM Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia
Jun 21, 2021 08:40AM Moleculin Biotech (MBRX) Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
Jun 21, 2021 08:35AM Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
Jun 15, 2021 09:05AM Moleculin Announces Inclusion in the Russell 2000® Index
Jul 15, 2020 07:31AM Moleculin Biotech (MBRX) Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
Jul 15, 2020 07:30AM Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
Apr 23, 2019 09:24AM Pre-Open Stock Movers 04/23: (GNC) (HAS) (TWTR) Higher; (MBRX) (WAT) (HRL) Lower (more...)
View More Recent Stories View Older Stories